All In Biotech

Investigational drug · Phase 2

SPVN06

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Retinitis Pigmentosa.

Phase 2

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "SPVN06"

First trial start

2023

Apr 12, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SPVN06", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Retinitis Pigmentosa

Approved drugs for the same conditions: Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "SPVN06" as an intervention, largest first.

All trials
  • SparingVisionIndustry

    NCT05748873 · 33 participants · Start Apr 12, 2023 · Primary completion Feb 2027

    Drug: SPVN06 · For: Retinitis Pigmentosa

    Sites: Miami, Florida; Boston, Massachusetts; Portland, Oregon · 6 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Retinitis Pigmentosa

  • BS01Phase 22 trials

    Bionic Sight LLC · Retinitis Pigmentosa, Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)

  • CPK850Phase 21 trial

    Novartis · Retinitis Pigmentosa

  • famzeretcelhuman retinal progenitor cells, jCellPhase 21 trial

    jCyte, Inc · Retinitis Pigmentosa

  • KIO-301Phase 21 trial

    Kiora Pharmaceuticals, Inc. · Retinitis Pigmentosa

  • OCU400Phase 21 trial

    Ocugen · Retinitis Pigmentosa, Leber Congenital Amaurosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.